although
interferon
ifn
ifng
report
exhibit
synergist
antivir
effect
differ
signal
pathway
vitro
therapeut
efficaci
well
defin
vivo
current
studi
carri
investig
combin
antivir
effect
model
mous
hepat
viru
type
infect
fulmin
hepat
develop
inject
intraperiton
icr
mice
ifn
vehicl
administ
intramuscularli
day
antivir
effect
evalu
base
surviv
period
liver
histolog
serum
alanin
transaminas
alt
level
viru
titer
liver
tissu
anim
group
treat
combin
ifna
ifng
surviv
longer
period
group
treat
ifna
alon
ifng
alon
ifna
iumous
g
vs
ifna
p
ifna
g
vs
ifng
p
consist
lower
level
hepatocellular
necrosi
serum
alt
decreas
titer
viru
liver
tissu
hr
p
hr
p
find
indic
combin
ifna
ifng
exhibit
synergist
antivir
effect
infect
biolog
quit
differ
human
hepat
virus
howev
result
suggest
benefici
combin
therapi
ifna
ifng
treatment
human
viral
hepat
interferon
ifn
use
wide
treatment
chronic
hepat
c
therapeut
effect
ifna
determin
viru
titer
extent
variou
factor
consid
involv
enomoto
et
al
mizokami
et
al
improv
therapeut
effect
patient
ifnaresist
chronic
hepat
c
type
ifna
heathcot
et
al
zeuzem
et
al
administr
period
kasahara
et
al
administr
method
fujiwara
et
al
investig
new
therapeut
method
combin
therapi
ifn
ribavirin
davi
et
al
mchutchison
et
al
viral
genetarget
therapi
macejak
et
al
attempt
suffici
efficaci
attain
howev
new
therapeut
method
improv
efficaci
ifn
therapi
need
ifn
known
activ
ifnstimul
gene
antivir
effect
exhibit
protein
induc
ifn
oligoadenyl
synthetas
oa
doublestrand
rnadepend
protein
kinas
pkr
mx
protein
samuel
der
et
al
ifn
classifi
type
ifn
ifna
b
type
ii
ifn
ifng
ifna
consist
mani
subtyp
molecular
form
type
type
ii
ifn
signal
via
differ
receptor
type
type
ii
allen
et
al
report
although
signal
transduct
pathway
differ
ifna
ifng
darnel
et
al
synergist
gene
express
induc
combin
ifna
ifng
levi
et
al
thoma
et
al
matsumoto
et
al
mizukoshi
et
al
although
combin
therapi
ifna
ifng
studi
clinic
katayama
et
al
kumashiro
et
al
effect
action
mechan
investig
fulli
current
studi
undertaken
investig
whether
concurr
administr
ifna
ifng
increas
antivir
effect
model
mous
hepat
viru
type
infect
mous
hepat
viru
mhv
posit
singlestrand
rna
viru
belong
coronavirida
lee
et
al
compton
et
al
experi
provid
professor
kyuwa
depart
anim
patholog
institut
medic
scienc
univers
tokyo
use
known
caus
fulmin
hepat
inbr
icr
mous
strain
jone
cohen
propag
quantit
accord
method
report
hirano
et
al
hirano
et
al
use
murin
delay
brain
tumor
dbt
cell
provid
professor
kyuwa
dbt
cell
cultur
eagl
minimum
essenti
medium
mem
gibco
brl
rockvil
md
contain
fc
gibco
brl
tryptas
phosphat
broth
tpb
gibco
brl
co
propag
cultur
medium
discard
dbt
cell
form
monolay
cultur
dish
ml
stock
solut
adsorb
dbt
cell
hr
ml
cultur
medium
ad
cell
cultur
hr
obtain
cultur
fluid
frozen
stock
solut
immedi
experi
quantit
monolay
dbt
cell
petri
dish
infect
ml
sampl
min
mem
first
overlay
medium
contain
tpb
fc
nobl
agar
difco
laboratori
detroit
mi
ad
cell
cultur
anoth
day
mem
secondari
overlay
medium
contain
neutral
red
ad
number
plaqu
measur
hr
mous
hepat
model
prepar
singl
intraperiton
inocul
ml
suspens
adjust
contain
plaqueform
unit
pfu
ml
cultur
medium
male
icr
mice
charl
river
japan
yokohama
japan
anim
care
procedur
carri
use
criteria
outlin
guid
care
use
laboratori
anim
prepar
nation
academi
scienc
publish
nation
institut
health
nih
public
revis
group
consist
anim
ifn
treatment
group
ifn
administ
intramuscularli
im
femor
muscl
daili
day
inocul
day
inocul
ifn
dissolv
adjust
mous
albuminsuppl
physiolog
salin
ifn
recombin
mous
interferon
rmifn
provid
hayashibara
biochem
laboratori
inc
okayama
japan
ifn
dosag
group
treat
singl
type
ifn
ifna
ml
mous
ifng
mlmous
combin
treatment
group
ifna
g
ifna
g
mlmous
control
group
receiv
administr
volum
vehicl
mous
albuminsuppl
physiolog
salin
surviv
period
day
inocul
investig
group
simpl
comparison
surviv
period
kaplanmei
surviv
curv
use
surviv
period
analyz
surviv
period
test
program
use
sa
system
sa
institut
japan
determin
synerg
surviv
period
test
surviv
period
test
program
twoway
layout
anova
use
sa
system
compar
among
group
among
total
ifn
unit
administ
surviv
curv
prolong
significantli
combin
treatment
group
comparison
effect
judg
synergist
control
group
group
treat
singl
type
ifn
ifna
ifng
combin
treatment
group
ifna
g
n
group
three
anim
sacrif
daili
day
mhv
inocul
group
liver
tissu
stain
hematoxylin
eosin
time
point
examin
light
microscop
control
group
group
treat
singl
type
ifn
ifna
ifng
combin
treatment
group
ifna
g
n
group
anim
kill
day
inocul
group
serum
alanin
transaminas
alt
level
viru
titer
liver
tissu
investig
serum
alt
level
measur
use
transaminas
ciitest
wako
wako
pure
chemic
industri
ltd
osaka
japan
measur
viru
titer
liver
tissu
g
wet
liver
tissu
homogen
ml
cultur
medium
quantifi
plaqu
assay
avoid
variat
among
assay
mice
suppli
time
divid
group
ifn
administr
inocul
carri
day
group
valu
express
mean
ae
sd
comparison
two
group
analyz
wilcoxon
ranksum
test
synergist
effect
viru
titer
analyz
twoway
anova
use
sa
system
pvalu
consid
signific
control
group
anim
die
within
day
inocul
fig
group
treat
ifna
alon
iumous
surviv
period
prolong
significantli
compar
control
group
ifna
p
ifna
p
ifna
p
fig
similarli
group
treat
ifng
alon
iu
mous
surviv
period
significantli
prolong
ifng
p
ifng
p
fig
interestingli
anim
treat
combin
ifna
ifng
iumous
surviv
longer
period
anim
treat
ifna
alon
ifng
alon
ifna
g
vs
ifna
p
ifna
g
vs
ifng
p
effect
synergist
p
fig
dose
ifna
ifng
increas
surviv
period
also
prolong
ifna
g
combin
group
compar
group
treat
either
ifn
fig
control
group
submass
massiv
necrosi
observ
liver
tissu
day
inocul
hepatocellular
necrosi
progress
replic
liver
fig
group
treat
ifng
alon
sever
almost
level
control
group
contrast
group
treat
ifna
alon
spotti
necrosi
observ
one
three
anim
day
inocul
hepatocellular
necrosi
observ
two
anim
ifna
g
combin
group
hepatocellular
necrosi
observ
day
inocul
spotti
necrosi
observ
two
three
anim
day
inocul
howev
hepatocellular
necrosi
observ
remain
one
anim
group
treat
ifna
alon
ifna
g
combin
hepatocellular
necrosi
obvious
mild
compar
control
group
fig
tabl
serum
alt
level
day
inocul
control
group
day
n
day
n
group
treat
ifna
alon
day
n
day
n
ifng
alon
day
n
day
n
ifna
g
combin
day
n
day
n
shown
figur
serum
alt
level
day
inocul
significantli
lower
group
treat
ifna
g
combin
compar
group
treat
ifna
alon
ifng
alon
ifna
g
vs
ifna
p
ifna
g
vs
ifng
p
serum
alt
level
day
inocul
significantli
lower
group
treat
ifna
g
combin
compar
group
treat
ifna
alon
ifna
g
vs
ifna
p
ifna
g
vs
ifng
p
titer
liver
tissu
day
inocul
control
group
day
n
day
n
group
treat
ifna
alon
day
n
day
n
ifng
alon
day
n
day
n
ifna
g
ifng
p
ifng
p
surviv
prolong
significantli
compar
control
combin
day
n
day
n
shown
figur
control
group
titer
liver
tissu
day
inocul
ae
ae
log
pfug
wet
tissu
respect
group
treat
ifna
alon
titer
liver
tissu
day
inocul
ae
ae
log
pfug
wet
tissu
respect
group
treat
ifng
alon
titer
liver
tissu
day
inocul
ae
ae
log
pfug
wet
tissu
respect
group
treat
ifna
g
combin
titer
liver
tissu
day
inocul
ae
ae
log
pfug
wet
tissu
respect
comparison
among
control
group
group
treat
ifna
alon
ifng
alon
ifna
g
combin
show
viru
titer
liver
tissu
decreas
significantli
group
treat
ifna
g
combin
day
inocul
effect
synergist
day
p
day
p
fig
mous
hepat
viru
type
induc
hepat
model
use
determin
potenti
antivir
effect
combin
ifna
ifng
report
exogen
mifnab
administr
prolong
surviv
mous
hepat
model
kato
et
al
report
also
administr
rifnab
hr
simultan
mhv
inocul
effect
chronic
hepat
model
induc
attenu
viru
uetsuka
et
al
ifng
receptor
defici
mice
shown
infect
easili
mhv
schijn
et
al
kyuwa
et
al
b
show
administr
rifng
prolong
surviv
mousehepat
viru
strain
jhminfect
ifng
receptor
defici
mice
note
import
ifng
elimin
viru
zhang
et
al
show
vitro
antivir
effect
ifng
mhv
occur
ifng
administ
hr
mhv
inocul
base
find
ifn
administr
initi
day
inocul
studi
surviv
period
prolong
dosedepend
manner
group
treat
ifna
alon
surviv
curv
prolong
significantli
compar
control
group
group
treat
ifng
alon
signific
prolong
surviv
curv
observ
compar
group
treat
ifna
alon
although
statist
signific
margin
confirm
prolong
life
ifn
interestingli
anim
group
treat
combin
ifna
ifng
surviv
longer
period
group
treat
ifna
alon
ifng
alon
ifna
g
spotti
necrosi
focal
necrosi
submass
necrosi
massiv
necrosi
mice
treat
ifna
ml
per
mous
n
ifng
ml
per
mous
n
alon
combin
n
control
mice
inject
im
colum
vehicl
ifna
alon
ifnag
combin
degre
hepatocellular
necrosi
milder
control
fig
comparison
chang
serum
alt
level
time
cours
mice
treat
ifna
day
n
day
n
ifng
hour
n
day
n
alon
combin
day
n
day
n
control
mice
inject
im
volum
vehicl
day
n
day
n
data
express
mean
ae
sd
serum
alt
day
infect
serum
alt
level
ifna
ifng
treat
mice
significantli
lower
ifna
mice
p
ifng
treat
mice
p
day
inocul
serum
alt
level
decreas
significantli
compar
group
treat
ifna
alon
ifna
g
vs
ifna
p
ifna
g
vs
ifng
p
p
p
fig
antivir
effect
treatment
ifn
replic
mice
treat
ifna
day
n
day
n
ifng
day
n
day
n
alon
combin
day
n
day
n
control
mice
inject
im
volum
vehicl
day
n
day
n
viru
titer
liver
tissu
decreas
significantli
group
treat
ifna
g
combin
time
point
compar
group
treat
ifna
alon
ifng
alon
effect
synergist
day
p
day
p
twoway
anova
use
sa
system
p
liver
homogen
prepar
viru
titer
determin
plaqu
assay
histolog
examin
liver
tissu
biochem
examin
quantit
liver
tissu
carri
group
treat
ifna
g
combin
ifna
alon
ifng
alon
histolog
examin
degre
hepatocellular
necrosi
mild
group
treat
ifna
alon
ifnag
combin
compar
control
group
indic
progress
hepatocellular
necrosi
inhibit
ifn
administr
find
consist
signific
decreas
serum
alt
level
day
inocul
mhv
titer
consid
major
caus
hepatocellular
necrosi
hepat
model
amount
viru
consid
determin
degre
hepatocellular
necrosi
surviv
rate
investig
whether
viru
titer
liver
tissu
decreas
administr
ifn
found
viru
titer
decreas
significantli
time
point
group
treat
ifnag
combin
therefor
shown
exogen
administr
ifnag
combin
synergist
inhibit
viral
titer
liver
may
inhibit
progress
hepatocellular
necrosi
also
prolong
surviv
synergist
manner
liver
damag
howev
measur
serum
alt
level
reduc
synergist
one
reason
discrep
low
titer
still
induc
mild
hepatocellular
necrosi
despit
fact
viral
titer
liver
lower
tenfold
respect
ifna
ifng
alon
interact
mechan
ifna
ifng
activ
ifnstimul
gene
factor
ifng
shown
matsumoto
et
al
levi
et
al
report
treatment
hela
cell
ifng
ifna
induc
increas
synthesi
latent
subsequ
activ
respons
ifna
form
level
higher
level
detect
cell
treat
ifna
alon
show
synergist
effect
shown
ifng
induc
express
mrna
treatment
ifng
follow
administr
ifna
significantli
increas
intracellular
oa
activ
compar
treatment
ifna
alon
mizukoshi
et
al
takaoka
et
al
found
new
signal
cross
talk
system
ifna
ifng
receptor
level
caveola
membran
domain
mous
embryon
fibroblast
activ
complex
antivir
activ
decreas
phosphoryl
amount
recruit
increas
stimul
ifng
show
activ
via
note
signal
transduct
ifng
may
made
potent
effici
use
system
via
ifnab
receptor
synergist
antivir
effect
ifna
ifng
caus
system
clear
whether
mechan
describ
reflect
directli
studi
synergist
gene
express
induc
combin
ifna
ifng
may
potenti
antivir
effect
suggest
investig
express
level
oa
necessari
regard
immunolog
background
report
hepat
model
aj
mous
type
thelper
cytokin
activ
resist
wherea
balbc
mice
cytokin
activ
easili
infect
liu
et
al
studi
action
cytokin
induc
ifng
may
effect
viru
elimin
addit
vitro
synergist
gene
express
induc
concurr
administr
ifna
ifng
present
studi
show
synergist
antivir
effect
combin
therapi
ifna
ifng
coronaviru
vivo
sever
public
argu
use
ifna
ifng
combin
therapi
human
viral
hepat
krampera
et
al
bergamini
et
al
kumashiro
et
al
investig
necessari
howev
studi
suggest
combin
therapi
ifna
ifng
may
becom
therapeut
method
treatment
viral
hepat
man
method
synergist
antivir
effect
may
improv
efficaci
ifn
therapi
